SUCLG2 and colorectal carcinoma: Overall, this was the first research to construct and validate a prognostic 8-FAMGs signature depending upon the expression of ACBD4, ACOX1, CD36, CPT2, ELOVL3, ELOVL6, ENO2, and SUCLG2 for CRC individuals under strict standards.